Adams Asset Advisors LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 1.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 119,076 shares of the biopharmaceutical company’s stock after selling 1,440 shares during the period. Adams Asset Advisors LLC’s holdings in Pfizer were worth $4,192,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the company. Catamount Wealth Management increased its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Stuart Chaussee & Associates Inc. increased its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the period. Financial Strategy Network LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $205,000. Oakmont Partners LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $211,000. Finally, Arete Wealth Advisors LLC increased its stake in shares of Pfizer by 11.3% in the first quarter. Arete Wealth Advisors LLC now owns 7,172 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 726 shares during the period. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded up 0.15% on Monday, reaching $33.61. The company’s stock had a trading volume of 16,383,660 shares. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39. The firm has a market cap of $203.87 billion, a PE ratio of 29.80 and a beta of 0.86. The stock’s 50 day moving average price is $34.25 and its 200 day moving average price is $34.28.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.56 EPS. Equities research analysts expect that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.57%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
Several analysts have commented on PFE shares. Jefferies Group dropped their target price on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, June 20th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target for the company. in a research note on Tuesday, June 28th. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 25th. Finally, JPMorgan Chase & Co. set a $40.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 25th. Ten equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.